TOMI Secures $450,000 Contract for Custom Engineered System (CES) Installation
This contract further emphasizes the effectiveness and adaptability of TOMI's SteraMist technology. Additionally, TOMI is in negotiations with a long-standing client in Boston, an early adopter of CES, for a potential upgrade and expansion project. There is clear demand among academic institutions for enhanced decontamination solutions, as TOMI's cutting-edge technology continues to demonstrate superior performance compared to traditional hydrogen peroxide systems.
As Boston's life science industry anticipates a rebound in 2025, TOMI's SteraMist iHP technology is poised to remain a preferred choice for disinfection requirements. Earlier this quarter, TOMI secured another sale with the addition of a SteraPak system at a private university in Massachusetts. The recent university contract adds to our impressive portfolio in the New England territory, which includes over twenty (20) separate biotechnology, pharmaceutical, and research university customers.
"We are thrilled to see the continued adoption and expansion of SteraMist technology in New England, a region renowned for its concentration of life science innovation and world-class educational and research institutions," said Elissa J. (E.J.) Shane, COO of TOMI Environmental Solutions. "These orders, and those to come, not only validate the efficacy of our solutions but also reflect our commitment to providing cutting-edge disinfection technologies to support the critical work being done in these American institutions."
TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.
For additional information, please visit http://www.steramist.com or contact us at info@tomimist.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management's judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI's products to serve life science markets in New England. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.
INVESTOR RELATIONS CONTACT:John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Medpace (MEDP) Q2 Earnings Report Preview: What To Look For
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting results this Monday after market hours. Here's what to expect. Medpace beat analysts' revenue expectations by 6% last quarter, reporting revenues of $558.6 million, up 9.3% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' organic revenue estimates and an impressive beat of analysts' EPS estimates. Is Medpace a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Medpace's revenue to grow 2.6% year on year to $542 million, slowing from the 14.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.00 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medpace has missed Wall Street's revenue estimates five times over the last two years. With Medpace being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for life sciences tools & services stocks. However, the whole sector has been hit hard over the last month as stocks in Medpace's peer group are down 2.5% on average. Medpace's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $301.61 (compared to the current share price of $311.86). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Earnings To Watch: Preferred Bank (PFBC) Reports Q2 Results Tomorrow
Commercial banking company Preferred Bank (NASDAQ:PFBC) will be announcing earnings results this Monday before market open. Here's what investors should know. Preferred Bank missed analysts' revenue expectations by 5.5% last quarter, reporting revenues of $66.66 million, down 6.9% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' net interest income estimates and a miss of analysts' EPS estimates. Is Preferred Bank a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Preferred Bank's revenue to grow 1.9% year on year to $70.82 million, a reversal from the 9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.43 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Preferred Bank has missed Wall Street's revenue estimates three times over the last two years. Looking at Preferred Bank's peers in the regional banks segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Texas Capital Bank delivered year-on-year revenue growth of 15.2%, beating analysts' expectations by 2.7%, and Nicolet Bankshares reported revenues up 12.7%, topping estimates by 4.4%. Texas Capital Bank traded up 4.8% following the results while Nicolet Bankshares was also up 7.8%. Read our full analysis of Texas Capital Bank's results here and Nicolet Bankshares's results here. There has been positive sentiment among investors in the regional banks segment, with share prices up 10.3% on average over the last month. Preferred Bank is up 13.8% during the same time and is heading into earnings with an average analyst price target of $93.75 (compared to the current share price of $92.61). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
BOK Financial (BOKF) Q2 Earnings: What To Expect
Regional banking company BOK Financial (NASDAQ:BOKF) will be reporting earnings this Monday after the bell. Here's what you need to know. BOK Financial missed analysts' revenue expectations by 3.2% last quarter, reporting revenues of $502.3 million, up 9.8% year on year. It was a softer quarter for the company, with a significant miss of analysts' EPS estimates and net interest income in line with analysts' estimates. Is BOK Financial a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting BOK Financial's revenue to decline 7.1% year on year to $518.4 million, a reversal from the 4.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.99 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BOK Financial has missed Wall Street's revenue estimates three times over the last two years. Looking at BOK Financial's peers in the regional banks segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Texas Capital Bank delivered year-on-year revenue growth of 15.2%, beating analysts' expectations by 2.7%, and Nicolet Bankshares reported revenues up 12.7%, topping estimates by 4.4%. Texas Capital Bank traded up 4.8% following the results while Nicolet Bankshares was also up 7.8%. Read our full analysis of Texas Capital Bank's results here and Nicolet Bankshares's results here. There has been positive sentiment among investors in the regional banks segment, with share prices up 10.3% on average over the last month. BOK Financial is up 14.3% during the same time and is heading into earnings with an average analyst price target of $106.60 (compared to the current share price of $105.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
